Linkage Biosciences
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $1.0m | Seed | |
$2.0m | Series A | ||
N/A | $2.0m | Early VC | |
$2.1m | Series B | ||
$2.0m | Early VC | ||
$1.5m | Early VC | ||
$2.0m | Early VC | ||
N/A | Acquisition | ||
Total Funding | CAD17.2m |
Recent News about Linkage Biosciences
EditLinkage Biosciences specializes in advanced diagnostic tests that determine donor compatibility before transplants and monitor HLA antibodies post-transplant to prevent rejection. Operating in the healthcare and biotechnology market, the company serves hospitals, transplant centers, and laboratories. Its business model revolves around the development and sale of diagnostic assays, leveraging multiplex PCR technology for simplicity and efficiency. Revenue is generated through the sale of these diagnostic kits and related services. Linkage Biosciences aims to support the transplantation community with innovative solutions and resources, particularly during challenging times like the Covid-19 pandemic.
Keywords: diagnostic tests, donor compatibility, HLA antibodies, transplant success, multiplex PCR, healthcare, biotechnology, transplant centers, diagnostic assays, Covid-19.